Tscan therapeutics announces presentation at the h.c. wainwright cell therapy virtual conference

Waltham, mass., feb. 21, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that the company will present at the h.c. wainwright cell therapy virtual conference on tuesday, february 28, 2023, at 3:30 p.m. eastern time.
TCRX Ratings Summary
TCRX Quant Ranking